Smith & Nephew Plc
20 June 2003
20 June 2003
Smith & Nephew Close Period Trading Update
Smith & Nephew plc, the advanced medical devices group, has continued to achieve
strong double-digit sales growth during the first half of 2003 in its largest
and fastest-growing business - Orthopaedics. Overall underlying sales growth
for Smith & Nephew in the first half of 2003 is expected to be around 10%.
Acquisitions will add 1% to this growth, but currency will be 3% adverse.
Orthopaedics will lead the group with underlying sales growth of around 15% as
anticipated, with continued strong reconstructive growth of 19% and trauma
growth of 10%. Wound Management's underlying growth is running at 7%, a slower
than expected start, largely due to delays in production expansion in the US.
Sales of Dermagraft are on track and we expect Wound Management to return to
previous growth levels in the second half. As previously indicated, we
anticipate Endoscopy's sales growth will slow to 5%, mainly due to increased
blade reuse in the US, but is expected to improve for the full year with a
number of new product launches in the second half.
Sir Christopher O'Donnell, Chief Executive of Smith & Nephew said, 'We are
pleased with the growth of our orthopaedics business and believe increased sales
of new products will accelerate our overall sales growth in the second half of
the year. We remain on track to meet our full-year financial targets.'
Smith & Nephew is to give a briefing to investors and analysts today ahead of
the close period, which precedes its interim results announcement. The briefing
will be via conference call at 3 pm UK time, and can be heard by live audio
webcast via the Smith & Nephew website at www.smith-nephew.com. A recording of
the briefing will be available on the Smith & Nephew website after the call.
Smith & Nephew, whose business is focused on the fast growing markets for
orthopaedics, endoscopy and advanced wound management products, will report
interim results on 31 July.
Enquiries:
Smith & Nephew
Angie Craig Tel: +44 (0)20 7401 7646
Corporate Affairs Director
Financial Dynamics
David Yates Tel: +44 (0)20 7831 3113
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.